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1. Introduction 
 
1.1 Invasive mechanical ventilation 
 
Invasive mechanical ventilation is a lifesaving intervention for patients with acute, severe 
respiratory failure. Numerous medical conditions can lead to respiratory failure, but fall 
broadly into two categories: neuro-muscular disorders leading to hypoventilation, or 
processes within the lungs impairing gas exchange. The latter may originate in the lungs, 
such as severe pneumonia, autoimmune and degenerative lung diseases, or have extra 
pulmonary causes secondarily affecting the lungs, such as severe sepsis, acute pancreatitis 
and multiple trauma. Invasive ventilation is not without risks, and ventilator-associated 
pneumonia (VAP) is a major complication.  VAP is, however, difficult to diagnose with 
certainty, and its attributable mortality is debated.  
 
The lungs react in a stereotypical way to a range of insults. The term acute respiratory 
distress syndrome (ARDS) was coined acknowledging this, the definition being descriptive, 
involving a severe lowering of the ratio of inspired oxygen to oxygen in the blood, and 
bilateral  chest X-ray infiltrates in the absence of cardiac disease explaining these 
abnormalities. Infections originating inside or outside the lungs, multiple trauma and 
abdominal catastrophes are common causes of ARDS. Bacterial infections are the most 
common, but viral infections also have the potential to cause ARDS. This was demonstrated 
during the Hantavirus Pulmonary Syndrome epidemic, the Severe Acute Respiratory 
Syndrome (SARS) epidemic of 2004, and, more recently, during the pdm(H1N1)  influenza 
pandemic, where influenza remerged as an important cause of ARDS (1-  3) .  
 
The main objectives of this thesis are to investigate airway microbiology, pulmonary 
infectious complications, and prognostic markers in patients on invasive mechanical 
ventilation, and to study host responses in ARDS caused by the new pdm (H1N1) influenza 
in particular. 
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1.2 Ventilator associated pneumonia 
 
1.2.1 Pathogenesis. 
Pneumonia occurs when a critical mass of sufficiently virulent bacteria reach the alveoli, 
overwhelms the local immune defence,  multiply and invade neighbouring alveoli before 
immune cells recruited from the blood and lymphatic vessels can contain the process. VAP 
is the result of this sequence of events occurring in mechanically ventilated patients. 
Bacteria reaching the alveoli are a frequent event, and an autopsy study of patients dying of 
non-medical causes demonstrated oropharyngeal flora in the lungs of all the deceased (4). 
Micro aspiration of oropharyngeal fluids also occurs on a regular basis (5). In patients on 
invasive mechanical ventilation, a shift in the oropharyngeal flora occurs, introducing 
bacteria with possible higher virulence than the normal flora. The lungs are well equipped to 
deal with this continuous bacterial challenge, as they have a unique capacity toinduce the 
innate immune response. Alveolar macrophages detect pathogens with the help of pattern-
recognition receptors, phagocytise bacteria and, if overwhelmed, recruit the main effector 
cells of the innate immunity, the neutrophiles (6). Antibacterial peptides are abundant 
throughout the lower airways, and play a role in killing bacteria before they reach the 
alveoli. The consequence of malfunction of this defence system is seen in cystic fibrosis. 
(7). The concept of a critical bacterial mass shifting the balance from a manageable 
challenge to pneumonia is recognized, and in various mouse models, inoculation of 
increasing concentrations of  pneumococci in the alveoli, ultimately leads to pneumonia and 
death of the animals (8;9). 
 
After endotracheal intubation, major defence mechanisms are broken, leading to an increase 
in the amount of bacteria reaching the alveoli. The intubation procedure itself frequently 
introduces a significant number of bacteria into the normally sterile distal airways. This is 
reflected in the clinical experience of a peak in the incidence of VAP of 3% per day in the 
first 4 days after intubation, thereafter falling to a daily incidence of 1% (10). The main 
bacterial reservoir feeding the distal airways, are the heavily contaminated oropharyngeal 
secretions accumulating above the endotracheal cuff, running into the lungs along the folds 
of the cuff surface and the tracheal wall of virtually all intubated patients (11). Detachment 
of bacterial colonies from endotracheal tube biofilm has been shown to occur regularly 
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during each inspiratory cycle, and these repeated bacterial exposures could overwhelm 
defences and lead to VAP (12). Contaminated condense water aggregating in the ventilator 
circuits can be inadvertently emptied or aerosolized into the endotracheal tube, but this 
mechanism, once thought to be a major source of airways contamination, probably plays a 
minor role (13;14). The mechanisms of clearing gross collections of fluids and mucus in the 
airways, such as cough reflex and mucociliar clearance, are heavily impaired by the 
endotracheal tube and sedation of the patient. Damage to the mucosa from the intubation 
procedure or from pressure and movement of the cuff during ventilation can denude the 
mucosa and expose bacterial binding sites (15). A state of relative immunosuppression 
following the inflammatory response of  major surgery or sepsis is also contributing to 
increased vulnerability to infections, including VAP (16;17).  
 
Ventilator-associated tracheobronchitis (VAT) has recently been proposed as an 
intermediate condition between airway colonization and VAP. The diagnostic criteria are 
fever, new or increased sputum production, positive cultures for tracheal aspirates, no other 
recognizable cause of fever, but with no radiographic infiltrate or evidence of pneumonia 
(18). In one study where these criteria were sharpened to include the requirement of tracheal 
bacterial counts of > 106 colony forming units (cfu)/ml, antibiotic treatment reduced both 
VAP incidence (13% vs 47%) and mortality (18 patients vs 47 patients) (19). The results 
from this study however, have not been reproduced.  The jury is still out regarding both the 
existence of bacterial tracheobronchitis as a distinct entity, and the effect of antibiotic 
treatment, and it is possible that a significant number of VAT cases actually represent VAP 
with the “new or progressive infiltrate” not visible on poor-quality portable chest 
radiographs (20). A continuum from low, to high level colonization, to tracheobronchitis 
and VAP is however biologically plausible.  
 
In summary, a shift in the oropharyngeal microbial flora, increased numbers of bacteria 
reaching the distal tracheobronchial tree, repeated episodes of bacterial inoculations, and 
reduced local and systemic defence mechanisms, all contribute to the frequent occurrence of 
pneumonia in the ventilated patient. 
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1.2.2 Diagnosis.  
VAP is defined as pneumonia occurring more than 48 hours after intubation (21). It is 
suspected when an intubated patient develops new or progressive infiltrates on chest X-ray, 
fever, leucocytosis and purulent tracheal secretions (22). These clinical criteria however, 
lack both sensitivity and specificity, and over the past 20 years numerous rigorous and 
labour-intensive studies have been performed to improve diagnostic accuracy. Most efforts 
have been made investigating the value of including airway sampling and quantization of 
bacteria, to the clinical criteria of VAP (21;23). Defining the optimal sampling sites, 
endotracheal or distal airways, mode of sampling, whether bronchoscopic or blind, and 
defining bacterial count threshold values separating colonization from infection have been 
the principal focus of research (24;25). Bronchoscopic sampling techniques include 
bronchoalveolar lavage (BAL) or protected specimen brush (PSB), with quantitative culture 
limits for differentiating bacterial infection from colonization of ≥104cfu/ml for BAL, and 
≥103cfu/ml for PSB. There is much controversy about the usefulness of this diagnostic 
approach. In 2004 the current state of affairs was summed up in an editorial : “Over 300 
studies have been published in peer-review journals in the past 8 years dealing with 
management of ventilator-associated pneumonia (VAP). However, no consensus exists to 
date on the best way of identifying patients with true lung infection.” (26). Seven years 
later, this statement is still valid. The lack of a gold standard for the diagnosis of VAP is a 
major obstacle to the design of studies aiming at improving diagnosis, and it is unlikely to 
be solved in the foreseeable future. Even the presumed histopathological gold standard of 
VAP has inherent limitations, such as sampling errors, inability to assert the age of the 
pneumonic lesions, and the bias of only being able to include deceased patients, or the rare 
patient upon whom an open lung biopsy has been performed. Enthusiasm for invasive 
sampling for diagnostic purposes has also been hampered by lack of evidence of improved 
outcome (27). A large randomized controlled trial (RCT) comparing invasive and non- 
invasive diagnosis for VAP, demonstrated reduced use of broad spectrum antibiotics, 
reduced 14 days mortality, and reduced organ failure at day 7 in the invasive diagnosis arm, 
but no difference in 28 days mortality (28). Furthermore, the other favourable results of the 
study were questioned as only one patient in the invasive diagnosis group received initial 
inadequate empiric antibiotic therapy versus 24 in the non-invasive group, thus possibly 
overestimating the effect of the intervention and underestimating the effect of inadequate 
therapy (29). With accumulating evidence of the role of early adequate antibiotic therapy as 
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the main prognostic factor in VAP (27;30-32), there is an increased recognition of the 
limitations of distal airway sampling and quantitative cultures for diagnostic purposes, as 
the result will arrive too late to influence treatment decision and initial antibiotic choice 
(33). An exception is information gained by direct microscopy as this could be used to rule 
out VAP if no bacteria are seen. In the influential American Thoracic Society / Infectious 
Disease Society of America (ATS/IDSA) guidelines on VAP, this point is taken into the 
decision tree on when to start or withhold treatment (34). However, other direct microscopy 
criteria have also been proposed, such as percentage of neutrophiles to total leukocytes, or, 
the number of BAL cells containing intracellular bacteria (35). Neither has been validated, 
and for the latter, widely differing thresholds of 1%, 5%, or 7%, respectively,  have been 
suggested (35;36). In clinical practice, concerns about sampling or processing errors, as well 
as the clinical judgment of the seriousness of the patient’s condition are likely to overrule 
treatment decisions based on microscopic findings. Distal airway sampling before 
commencing antibiotic treatment is still important in order to adjust antibiotic treatment 
when culture results become available as well as for re-evaluating the VAP diagnosis when 
uncertain and alternative diagnosis may have emerged since initiation of therapy. The 
microbiological epidemiology may vary considerably at country- and hospital level, 
sampling for surveillance purposes is, therefore essential for choosing adequate local 
empirical antibiotics regimens (37). Blood cultures and cultures of pleural fluids are  
important specimens for diagnosis, but are rarely positive in VAP, and as with airways 
samples, results come too late to influence initial therapy (38). Given the rarity of positive 
blood cultures in VAP, especially regarding gram-negative bacteria, this finding should 
prompt investigations of alternative sites before accepting the lungs as the source (39). The 
limitations of the bacteriological criteria for diagnosing VAP have led to search for 
alternative strategies, notably exploring host immune responses. Soluble triggering receptors 
expressed on myeloid cells (s-TREM-1), which are up-regulated on the surface of 
inflammatory cells in the presence of bacterial infections have been investigated as a 
potential marker of VAP. In 2004 a study was published where s-TREM-1 in BAL fluid 
performed favourably compared to combined clinical and microbiological criteria for 
diagnosing VAP (40). Several similar studies have been published since, some using serial 
measurements of s-TREM-1, or another widely investigated biomarker, pro-calcitonin 
(22;41). They all share the inherent limitation of the field, the lack of a gold standard for 
VAP diagnosis, thus, a biomarker-based approach merely speeds up diagnosis by bypassing 
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time-consuming bacterial cultures, not improving diagnostic accuracy as such. Schuetz et al. 
summarized in a recent review the way forward in biomarker research in infectious diseases: 
“only randomized controlled trials, in which antimicrobial therapy is guided by specific cut 
off ranges of the biomarkers and in which the primary measure of efficacy is medical 
outcome, have the potential to evaluate the ultimate clinical usefulness of a diagnostic 
biomarker” (42). This is also valid for biomarker studies using mRNA gene expression 
signatures of BAL or peripheral blood cells, to differentiate infections from other causes of 
respiratory failure. Although in its infancy, identification of a set of genes expressed only or 
predominantly in infections is promising (43). The merit must be evaluated as for other 
biomarkers, but the sheer number of simultaneously investigated genes with micro array 
technology promises better  differentiation between various clinical similar, but pathological 
different conditions, as opposed to current investigation of single gene products. This 
approach has already been successful in oncology, were clinical and histological similar 
cancers have been subdivided into a number of diseases with different prognosis and 
treatments (44).  
 
A formalized clinical evaluation in the form of a Clinical Pneumonia Infection Score (CPIS) 
has also been proposed to diagnose VAP (23). The scoring system assigns points based on 6 
clinical assessments, each worth 0 –2 points, including: fever, leukocyte count, quantity and 
purulence of tracheal secretions, oxygenation, type of radiographic abnormality, and results 
of sputum culture and Gram stain. When applied prospectively, sputum culture and Gram 
stain are unavailable and a modified scoring system, omitting culture results has been 
proposed by Singh et al. (45). In their study, aimed at reducing antibiotic overuse, 
antibiotics were safely discontinued if the CPIS score remained < 6 on day 3. For the day 3 
CPIS score calculation, results of culture and Gram stain were included. The aggregate 
score of CPIS is, however, very similar to a clinician using all available data to decide how 
strongly the diagnosis of pneumonia is suspected. The use of clinical criteria to initiate, and 
microbiological data to modify or terminate antibiotic therapy is now accepted as a standard 
of care (46). 
 
1.2.3 Treatment. 
The most important factors for outcome of VAP are early and adequate antibiotic therapy. 
Starting with a wrong antibiotic cannot be reversed by later antibiotic adjustments according 
 17 
to sensitivity testing, although this was recently contested in patients with less severe 
disease (27;30;32;47;48). The mainstay of therapy for VAP is therefore awareness, rapid 
diagnosis, and prompt treatment initiation, choosing an empiric antibiotic therapy that is 
appropriate to the local microbiological epidemiology. No single antibiotic or combination 
of antibiotics can be recommended over others, but activity against the core common 
bacteria: streptococci, S.aureus and enterobacteriacae, are necessary. The need to add 
coverage for methicillin resistant S. aureus (MRSA), P. aeruginosa and other non-
fermentors or multi-drug resistant enterobacteriacae, will depend on how likely these 
microbes are encountered locally. It is generally not considered necessary to give coverage 
for anaerobes or the frequently isolated Candida species (49). De-escalation to less broad 
coverage is recommended when culture results become available (50). One large RCT found 
8 days therapy to be equally effective to 15 days (51), and several studies have proposed 
criteria for early antibiotic discontinuation (52-54). ATS guidelines (1995) recommending 
7-10 days for uncomplicated and 14-21 days for more serious infections were not based on 
prospective studies (55). Copious airway secretions are removed with tracheal suctions 
when necessary, but should not be routinely scheduled. Chest physiotherapy, secretion 
removal with bronchoscopy, and coughing machines are widely used, but their impact is 
debated (56). 
 
1.2.4 Prognosis 
Crude mortality is high in ventilated patients, but assessment of mortality due to VAP, is 
complicated by the difficulty of precisely establishing the VAP diagnosis, and separate the 
VAP mortality from the mortality due to underlying disease. This problem increases with 
severity of underlying illness as the sickest patients will have the highest mortality, be the 
most vulnerable for acquiring VAP, and tolerate it the least. Thus, depending on patient 
population and VAP definitions, different figures of VAP-attributable mortality prevail. 
Craven et al reported 55% mortality in 49 patients treated with mechanical ventilation for 
nosocomial pneumonia, Kollef reported 37%, and Fagon et al. 71 % (57-59), the latter using 
PSB for diagnosis. Using a rigorous method matching ICU patients with and without 
pneumonia, VAP- attributable mortality was found to be 27 % (60). In the same study, 
pneumonia due to Pseudomonas and Acinetobacter, showed even higher attributable 
mortality rate of 42 %. Higher mortality due to these pathogens has also been demonstrated 
in other studies (61). Patient category also matters, no increased mortality of VAP was 
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found in trauma patients (62), and no difference in mortality was found for ARDS patients 
with or without concomitant VAP (63). Thus the impact of VAP is difficult to detect in 
conditions with low mortality, as in trauma or with high mortality, as in ARDS (38). An 
increased mortality in medical versus surgical patients was found in the Canadian Critical 
Care Trials Group (CCCTG), with a relative risk increase of 65% versus 27% (27). In this 
trial, the largest case-control study of mortality attributable to VAP, an absolute risk 
increase of 5, 8%, or a 33% relative risk increase of death was found, but the results did not 
reach statistical significance. The  27% VAP-attributable mortality found by Fagon and 
coworkers (60) versus zero VAP-attributable mortality in the study of Papazian et al.may 
also be due to the difference in the proportion of medical patients, 44% and 26% 
respectively (64).  
 
In conclusion, risk of death and risk of getting VAP covariate, posing inherent 
methodological problems delineating the mortality impact of VAP. Definite answers to 
VAP-attributable mortality would involve ethically unacceptable controlled studies 
withholding antibiotic treatment for VAP. The 33% relative risk estimates of the CCCTG 
probably reflect the best possible estimates with current diagnostic tools. 
1.3 Airway microbiology in mechanical ventilated patients  
 
Johnson et al. described, in 1969, the changing pharyngeal bacterial flora in hospitalized 
patients (65). They observed a marked increase in the prevalence of gram negative bacteria, 
not correlated to antibiotic exposure or length of hospitalization, but best correlated with the 
severity of underlying disease. Their findings were reproduced, and the causes for this 
transition were investigated, in several following papers (66-69). Niederman proposed three 
factors influencing microbial binding: epithelial cell variables, micro environmental 
variables, and bacterial variables (66;70).  
 
Fibronectin, an ubiquitous mammalian glycoprotein with diverse biological functions related 
to cell adhesion, has been implicated in confining epithelial attachment for the streptococci 
of normal oropharyngeal flora (71). Fibronectin is secreted with saliva and crevicular fluid 
(ultra filtrate of serum secreted trough oropharyngeal mucosa), and then coat the 
oropharyngeal mucosa (72). Loss of fibronectin has been shown to be important in enabling 
gram negative bacteria to adhere to, and colonize the oropharyngeal mucosa (71;73-75). 
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There are two possible explanations for the decreased epithelial fibronectin: Increased 
release of sputum leukocyte-derived proteases, and to a lesser extent, gram-negative 
bacteria-derived proteases, lead to increased cleaving of fibronectin from epithelial cell 
surfaces. In sick patients there is a reduced secretion of fibronectin from saliva and 
crevicular fluid (75). The importance of fibronectin on buccal cells has, however, been 
contested, and one study reported absence of fibronectin on normal buccal mucosa (76). 
Weinmeister et al. argued that a reduction of cell surface carbohydrates, notably galactose 
and sialic acid, is responsible for the increased binding of gram-negative bacteria. Though 
the responsible gram-negative bacteria binding cell surface structures are disputed  and 
probably involves multiple bacterial adhesins and mucosal surface receptors, the concept of 
a cell surface alteration caused by increased activity of respiratory tract proteases in the sick 
and more so in the critically ill, is similar (77).  
 
The micro-environmental changes caused by intubation are numerous. The foreign body 
surface of the endotracheal tube allows the formation of bacterial biofilms in which bacteria 
are protected from the immune system and largely unresponsive to antibiotics (12;78). The 
endotracheal cuff pools heavily contaminated fluid above the cuff, and causes damage to the 
mucosa, exposing binding sites for bacteria. Disruption of mucociliar function promotes 
prolonged mucosal contact with bacteria needed for colonization to occur. The endotracheal 
tube thus leads to an increase in both numbers and occasions for bacteria to seed the lungs. 
Lower airway colonization is also seen in non-intubated patients with micro-environmental 
changes and impaired mucocilar function, such as the H.influenzae colonization seen in 
chronic obstructive pulmonary disease (COPD), or the P. aeruginosa colonization seen in 
cystic fibrosis.P. aeroguinosa, has been shown to adhere poorly to intact ciliated epithelium, 
but adheres to damaged epithelium and basement membrane (79), possibly accounting for 
its frequency in VAP. A dynamic interaction between airway cells and bacteria has also 
been shown in a study with S.aureus; one hour after exposure, adherence to respiratory 
epithelium was low and inoculum independent, without damaging epithelial cells. However, 
at 24 hours more bacteria adhered, internalized bacteria were observed and a bacterial 
concentration-dependent cell necrosis occurred, suggesting a capacity for early defence but 
an increasing imbalance in host-pathogen interaction after prolonged bacterial exposure, 
such as seen in ventilated patients (80).  
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The bacteria recovered from endotracheal aspirates and BAL fluids are similar across 
several studies (28;62;63;81) see table 1. Local variations are considerable and surveillance 
cultures are mandatory for choosing appropriate local empiric regimens (37). 
 
TABLE1   
 ETIOLOGY OF VENTILATOR-ASSOCIATED PNEUMONIA 
AS DOCUMENTED BY BRONCHOSCOPIC TECHNIQUES IN 24 
STUDIES FOR A TOTAL OF 1,689 EPISODES AND 2,490 PATHOGENS 
 
Pathogen  Frequency (%) 
 
Pseudomonas aeruginosa  24.4 
Acinetobacter spp.  7.9 
Stenotrophomonas maltophilia  1.7 
Enterobacteriaceae*  14.1 
Haemophilus spp.  9.8 
Staphylococcus aureus   20.4 
Streptococcus spp.  8.0 
Streptococcus pneumoniae  4.1 
Coagulase-negative staphylococci  1.4 
Neisseria spp.  2.6 
Anaerobes  0.9 
Fungi  0.9 
Others (< 1% each)   3.8 
 
* Distribution when specified: Klebsiella spp., 15.6%; Escherichia coli, 
24.1%; Proteus spp., 22.3%; Enterobacter spp., 18.8%; Serratia spp., 
12.1%; Citrobacter spp., 5.0%; Hafnia alvei, 2.1%. 
 Distribution when specified: methicillin-resistant S. aureus, 55.7%; methicillin-
sensitive S. aureus, 44.3%. 
 Including Corynebacterium spp., Moraxella spp., and Enterococcus spp. 
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A distinction between early and late VAP, commonly defined as VAP occurring before or 
after 4 days of intubation, has in several studies been proposed to distinguish between likely 
non-multidrug resistant organisms in the former, and possible multidrug resistant (MDR) 
bacteria (MRSA, Extended Spectrum Beta Lactamase- and Karbapenemase producing 
gram-negative bacteria, Vancomycin Resistant Enterococci) in the latter (82). This 
distinction is based on the assumption that the longer the intensive care unit (ICU) stay, the 
greater the chance of acquiring ICU domestic MDR bacteria. The concept of early and late 
VAP has, however, been questioned, and no clear distinction between microbial findings 
were found in a recent large study (83). It is conceivable that knowledge of local 
microbiology offers a more powerful tool to decide whether empirical coverage for MDR 
organisms is required in individual ICUs (83). The source of the flora colonizing the 
airways in ventilated patients has been extensively investigated. The upper gastrointestinal 
tract, the sinuses, the circuits and tubes of the ventilator system, attending nursing personnel 
hands, have all been implicated (84). A consensus has evolved, and there is acceptance that 
the patients own airway and gastrointestinal flora is the reservoir for seeding of the distal 
airways (85). The composition of this reservoir changes according to the pathogens 
prevalent in the ICU and the effectiveness of hygiene measures in preventing acquisition of 
“in-house” microbes (86). The propensity to establish a gram-negative flora, and even more 
opportunistic bacteria, in the airways, is correlated to seriousness of underlying disease (87). 
Anaerobes, representing the majority of bacteria of both the upper and lower gastrointestinal 
tract, have long been covered in empiric regimes of VAP and in aspiration pneumonias. 
Several papers have questioned the necessity of anaerobe coverage and it is biologically 
plausible, that the aerobic environment created by the high oxygen concentrations delivered 
with mechanical ventilation, cannot promote anaerobe proliferation and infection (49). The 
need to treat Candida species, often recovered from airway samples in ventilated patients, 
has also been debated. Several well-designed studies have shown that the invasive potential 
of Candida in the airways is limited (88;89), and when Candida pneumonia occurs, it is in 
the context of haematogenous seeding after profound and prolonged neutropenia. 
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1.4 The pathophysiology and inflammatory response of Acute 
Respiratory Distress Syndrome (ARDS). 
 
The adult respiratory distress syndrome (ARDS) was described in 1967 in a dozen patients 
with refractory hypoxemia and diffuse lung infiltrates, the authors at the time recognizing 
that different insults could lead to the syndrome (90). In contrast to the neo-natal respiratory 
distress syndrome, lack of surfactant production from immature lungs is not the cause, and 
surfactant supplement not beneficiary. Acute respiratory distress syndrome is now the 
preferred term, recognizing that the same type of increased permeability oedema also occurs 
in children (91;92). In 1994, an expert group proposed an operational definition of ARDS, 
consisting of bi-lateral diffuse alveolar chest x-ray infiltrates, PaO2/FiO2 ratio < 27 kPa, in 
the absence of elevated left atrial pressure measured as pulmonary capillary wedge pressure 
with a pulmonary catheter ( PCWP < 18 mm Hg) when measured, or without clinical 
evidence of left atrial failure (93). Acute Lung Injury (ALI) was defined similarly, but on 
the less severe end of respiratory failure the PaO2/FiO2 ratio was set at 40 kPa. They further 
stated that ARDS is characterized by a constellation of clinical, radiological and 
physiological abnormalities that cannot be explained by, but may co-exist with, left atrial or 
pulmonary capillary hypertension. The definition is a tool for clinicians and scientists 
conducting research, but is not helpful for discriminating causes, or prognosis of ARDS. An 
acute and excessive inflammatory response driving the pathological changes to the lung 
parenchyma is at the core of ARDS (94). The large alveolar surface of 75 sqm, and the 
minimal 4-8 μm barrier between alveoli air surface and capillaries are an ideal construction 
for gas exchange, but is vulnerable to inflammatory processes disrupting that barrier. While 
local and systemic inflammation is a normal and adequate response to various insults, the 
failure to contain inflammation is not. ARDS can, like septic shock, be understood as a 
failure of “the checks and balances” of the innate immune response. The risk posed by 
inflammation was demonstrated in a transgenic mouse model where activation of NF-κB in 
lung epithelial cells was sufficient to cause neutrophil recruitment, pulmonary oedema, 
arterial hypoxemia, and cell death in the absence of any exogenous stimuli (95). 
Inflammation can be triggered by processes in the lungs as in pneumonia, aspiration, near-
drowning or inhalation of toxic gases, induced by infections outside the lungs, or by non-
infective causes, as pancreatitis, severe burns and multiple trauma. In ARDS caused by 
extra pulmonary insults, the inflammatory mediators, cytokines and activated leukocytes, 
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are carried by the blood to the lungs were they exert their effect (94;96). The course of 
ARDS can be divided into 3 phases, an acute exudative phase with activation and 
infiltration of leukocytes, increased  permeability of the capillary-endothelial barrier, with  
leakage of protein rich fluids into the alveoli (97), this increased permeability oedema being 
a hallmark of ARDS (94). A fibro proliferative phase, occurring on the second to seventh 
day after the initiating injury follows, were fibroblast infiltrate the site of inflammation and 
remodelling takes place, in most cases leading to full restitution, or contrarily, to 
progression to a fibrotic phase, with increasing fibrosis formation and  loss of function (98). 
These phases have been confirmed in histopathological studies, and they correlate more 
with time than with the initiating insult (99). 
 
Lately, the different elements of the inflammatory process, causing the clinical syndrome of 
ARDS, have been delineated, and details of the cytokine network, leukocytes and 
leukocytes derived inflammatory mediators elucidated (100). Cytokines.  Tumour necrosis 
factor-α (TNF-α) and interleukin-1β (IL-1β) are prototypically pro-inflammatory 
macrophage-derived cytokines, secreted shortly after insults like the injection of LPS or 
induction of pancreatitis (101), and in turn induce production of inflammatory cascades, 
inflammatory mediators, and up-regulate adhesion molecules on endothelial cells and 
leukocytes. In persistent ARDS, continuous high levels are found in BAL fluid (102). IL-6 
is produced in response to TNF-α and IL-1β stimulation, up-regulates the production of 
CRP, induces fever, and circulating levels correlate with severity of sepsis and pancreatitis-
induced ARDS (103). IL-10 curbs inflammation by inhibiting secretion of pro-inflammatory 
cytokines and up-regulating production of their soluble receptors, such as Il-1ra (104). Low 
circulating levels correlate with poor prognosis. Transforming Growth Factor-β (TGF- β) is 
important in fibrosis formation in several disease conditions, but is also important in tissue 
injury resolution (105;106). In ARDS, focus has been on TGF-β involvement in lung 
fibrosis formation in the fibroproliferative phase (107). Recent studies suggest that it is also 
a key mediator of acute lung injury by increasing endothelial permeability (108). Other 
cytokines includes granulocyte macrophage-colony stimulating factor (GM-CSF) a 
haematological growth factor, required for alveolar macrophage function, lung host defence, 
and surfactant homeostasis, where low levels have been associated with poor prognosis in 
sepsis (109). Chemokines, signalling molecules involved in attraction and activation of 
leukocytes to sites of inflammation, like the CC chemokines, IL-8, a potent leukocyte 
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attractant, and IP-10 a chemo attractant  for Th1 cells activating cell-mediated immune 
response, produced by bronchial epithelial cells in response to infection, have both been 
shown to correlate with mortality in ARDS (110;111). The CXC chemokines, monocyte 
chemo attractant protein (MCP)-1, and macrophage inflammatory protein (MIP)-1α,  also 
play a role in ARDS, with increased levels  shown to be associated with poor prognosis 
(112;113). In experimental models, neutralizing antibodies (114), or disruption of 
chemokine receptors have improved the outcome (115). The CXC chemokines have further 
been implicated in the residual pulmonary fibrosis developing during the fibroproliferative 
phase in a subset of ARDS patients (116). Future research is likely to identify other 
cytokines, as well as giving a better understanding of the complexity and redundancy of the 
cytokine network in ARDS. Activated neutrophile granulocytes.  The role of circulating 
and pulmonary polymorphonuclear leukocytes (PMN) as mediators of lung injury was 
recognized in the early 1980s, and is still central to the current concepts of ARDS. The 
detection of PMNs together with oedema fluid and hyaline membranes in autopsies (90),  
ultrastructural studies demonstrating the presence of increased numbers of intravascular and 
extravascular PMNs, platelets,  fibrin, as well as both endothelial and epithelial injury, and 
additional observations of increased PMN numbers in BAL fluid (117), testified to the role 
of inflammation and PMNs in ARDS (118). Under physiological conditions, circulating 
neutrophiles are in a resting state, and activation involves a series of co-ordinated events; 
the expression of cell-surface adhesion molecules (selectins and integrins), chemotaxis, the 
movement toward the site of inflammation through sensing of chemokine gradients, 
transendothelial migration and finally, phagocytises and/or release of inflammatory 
mediators and oxygen radicals. In parallel, a simultaneous up-regulation of adhesion ligands 
takes place on endothelial cells at the site of inflammation (119). The concept of activation 
of PMNs , by cytokines, after direct pathogen contact, complement activation, or other 
insults,  have thus been supplemented with the concept of a similar activation of  endothelial 
cells in  the lungs, induced in part by the same triggers (120). Interaction of activated 
circulating and pulmonary PMNs, activated pulmonal microvasculature, and the  effect of 
other locally produced or circulating inflammatory signalling and mediator molecules 
represent currently the best model for the pathophysiology of ARDS (119). The PMNs 
effector molecules, producing damage to the lungs are numerous. The “respiratory burst” 
producing oxygen radicals within the phagolysozome of PMNs, or released extracellularly 
in a controlled manner in an adequate inflammatory response, could in an exaggerated 
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response be released in quantities provoking tissue damage (121). This excessive production 
of oxygen radicals could be further enhanced by delivery of high oxygen concentrations 
during ventilator support (122). PMNs contain a large array of potential tissue damaging 
enzymes like elastases, collagenases, matrix metalloproteinases, gelatinases, released in an 
uncontrolled manner and without a counterbalanced secretion of their inhibitors, severe 
tissue injury could ensure (123;124). Finally, uncontrolled systemic complement activation 
can contribute to lung tissue injury, in part being central to activation and recruitment of 
PMN’s (125-127). This picture is simplified and other cells like circulating and pulmonal 
macrophages, and the lung parenchymal cells themselves almost certainly play a role in 
ARDS, as can be inferred by the fact that also profound neutropenic patients can develop 
ARDS (128). Knowledge of causes and consequences, and the basis of the immune 
dysregulation in ARDS on cytokine and cellular level, is poorly understood and a major 
obstacle to development of new interventions.  
 
Several components of ongoing inflammation like cytokine production, cell-proliferation 
and remodelling are responsive to glucocorticoid treatment, and thus several intervention 
studies in ARDS have been conducted. The failure of glucocorticoid therapy in reducing 
mortality, although decreasing ventilator and ICU days, was shown in a large randomized 
study (129). Reduced mortality with early and prolonged treatment (Two weeks at full dose, 
then tapered off > 2 weeks) with low-dose glucocorticoids ( Methylprednisolon 1 mg/kg per 
day for more than two weeks) was, however, reported in a successive multicenter study 
(130). Pooled data from four multicenter studies accounting for 472 patients showed that the 
relative risk of short-term mortality was 0,81 (CI 0,66-0,99) in favour of treatment with 
glucocorticoids (131). Differences may be related to timing of  treatment initiation, dosage 
and duration, as well as heterogeneity of patients (132). Future research to improve ARDS 
outcome will imply an approach to elucidate details of cellular and molecular 
pathophysiology, as well as intervention studies that are both large enough, and account for 
the dynamic nature of ARDS, where therapies may be effective at certain time points but 
not in others. 
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1.5 Pulmonary infections and lung pathology caused by Influenza 
virus 
 
Waterfowls and shorebirds are the natural reservoir of all subtypes of influenza A viruses, 
but the viruses can be transmitted to poultry, and, for some of the subtypes, to mammal 
species, including swine and humans. When sustained human to human transmission occurs, 
the viruses may cause pandemics, which upon adaptation to their human host, give rise to 
seasonal influenza outbreaks. A major factor for host specificity is receptor recognition, 
with avian viruses recognizing alpha 2,3 linked cellular receptors, present mainly in the 
lower respiratory tract of humans, while human-adapted influenza viruses recognize alpha 
2,6 linked cellular receptors, more widely distributed in the human upper respiratory tract, 
supporting active replication and transmission of the virus (133).  The recent pdm H1N1 
pandemic proved to give rise to mild disease, with notable exceptions, as in patients 
presented in the last paper of this thesis (134). At the outset of the pandemic, however, 
widespread fear prevailed about the possibility of large numbers of patients developing 
respiratory failure due to influenza, possibly overwhelming health care resources. 
Considering the high mortality observed in the highly pathogenic H5N1 influenza virus that 
emerged in 1997, and that the exact reason for the extreme number of deaths in the 1918 
“Spanish flu” is largely unknown or at least intensely debated, these fears are not 
unfounded. The 1918 virus has been reconstructed using reverse genetics. In both mouse 
and maquaque models the reconstructed virus was shown to propagate very efficiently, 
giving rise to a far higher number of viral copies than seasonal flu virus, as well as inducing 
a “cytokine storm”, possibly triggering uncontrolled and destructive inflammatory host 
response leading to respiratory failure (135;136). This has also been demonstrated in H5N1 
infections, and proposed as a reason for its high mortality (137). The 1918 H1N1 virus, 
however, did not harbour alterations in the HA cleaving site, and even displaying a highly 
pathogenic phenotype, with trypsin-independent replication, did not display  ∆ 146 
mutations, nor did it have a NS1 mutation, enhancing anti-interferon activity (138), three 
features otherwise proposed to explain the virulence of  highly pathogenic H5N1 influenza 
virus. Cleaving site alteration allows HA cleavage by a wide range of host proteases, not 
only confined to respiratory mucosal cells thus increasing organ tropism, and ∆ 146 
mutations have also been shown to alter cell tropism. Testing of single-gene reassortant 
1918 viruses identified the crucial role of HA, NA and PB1 segments in virus replication 
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and virulence (139).  In one study, however, where the authors gathered and analysed the 
extraordinary amount of contemporary data and studies generated during the 1918 
pandemic, including surviving histopathological samples, another conclusion was drawn: 
secondary bacterial infections was the main reason for the high death toll (140). The specific 
inflammatory patterns or regulation of immune response and the pathogenesis of the 
cytopathic effects of influenza in humans are incompletely understood. Humoral immunity 
with neutralising antibodies is important for preventing viral spread, its production is the 
goal of vaccines, and specific antibodies can abort or limit disease. Non-specific immunity 
is however of major importance and PMNs and alveolar macrophages are important for 
phagocytosis of influenza virions (141). The constitutional symptoms of influenza are 
explained by the release of various cytokines produced in the airway mucosa and release 
systemically, cytotoxic CD8+ cell response to infected cells, as well as natural killer cells 
induced apoptosis are important in clearing infected cells (142). Influenza gives rise to a 
variety of clinical pictures, ranging from mild cold symptoms to tracheobronchitis with 
pronounced constitutional symptoms, but severe alveolar inflammation, presenting as 
primary viral pneumonia, is rare (143). Seasonal influenza binds predominantly to α2,6-
linked cellular receptors which in humans are dominant in the upper airways, whereas the 
pdm (H1N1) virus also binds well to the α 2,3 gal receptors, which are present in the 
conjunctivae, distal airways, and alveolar pneumocytes, and may explain the ability of the 
virus to cause severe viral pneumonia (144). The D222G/N mutation in pdm (H1N1), seems 
to confer even higher affinity to α 2,3 receptors, further increasing the risk of  viral 
pneumonia. (145). The vast majority of patients infected with influenza virus experience 
mild upper respiratory tract disease or tracheobronchitis, but denuding of bronchial mucosa 
and impaired mucociliary clearance predisposes to secondary bacterial pneumonias (146). 
Frail patients may not tolerate this, but a major concern in influenza is the possibility of 
inducing severe viral pneumonia and respiratory failure in otherwise healthy patients (143). 
During the pdm H1N1 pandemic, viral pneumonia remerged as an important cause of 
ARDS (147). The role of specific host factors, viral mutants, or the interaction of both in 
severe pdm (H1N1) is poorly understood. Both a cytopathic effect as well as induction of an 
overshooting immune response could account for the lung pathology findings, and an 
increased viral replicative capability would enhance both (148). In patients dying from 
pdm(H1N1) infection, the  histopathological findings showed  varying degrees of diffuse 
alveolar damage with hyaline membranes and septal oedema, vascular congestion, 
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tracheitis, and necrotizing bronchiolitis. Bronchopneumonia and evidence of secondary 
bacterial pneumonia were found in 26% to 38% of cases (149;150). With the great 
importance of influenza to public health, further research to understand the pathology of 
influenza remains a priority. 
 
2. Aims of study 
 
Paper one 
To investigate the evolution of a local Pseudomonas aeruginosa outbreak caused by 
contaminated oral swabs in an ICU, and the impact on mortality and morbidity for 
mechanically ventilated patients being colonized in the airways with this pathogen. 
 
Paper two 
To investigate the patterns and dynamics of the microbial flora of the airways in 
mechanically ventilated patients,  the correlation of findings over time and airway locations, 
the effect of antibiotic therapy on recovery rates , and the correlation between serial chest 
X-rays findings and  bacterial counts in the distal airways. 
 
Paper three 
To investigate whether N terminal-pro atrial natriuretic peptide (NT-proANP) and N 
terminal pro brain natriuretic peptide (NT-proBNP) provide independent prognostic 
information in a consecutive series of critically ill patients requiring mechanical ventilation, 
admitted in the ICU for mainly non-cardiovascular diagnosis. To compare their relative 
prognostic value and see if they provide complementary prognostic information to 
conventional risk factors, including the SAPS II score, SOFA score and McCabe score. 
 
Paper four 
Investigate the immune response and role of viral factors in patients developing severe 
respiratory failure requiring mechanical ventilator support, caused by the new pdm (H1N1) 
influenza virus during the 2009 pandemic. 
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3. Summary of results 
 
Paper one 
Over the 5 month study period, defined as date of the first identification of the outbreak 
strain till last identified, 94 patients were admitted to the ICU. Forty-four were eligible for 
inclusion, fulfilling the criteria of at least 24 hours of mechanical ventilation and 
microbiological samples being collected. Eighteen (41%) of the patients became colonized 
with P. aeruginosa,. Colonization occured early with a median time to colonization of 4 
days, and 14 out of 18 patients became colonized within 9 days. Seven of the colonized 
patients became infected with P. aeruginosa,; 4 developed VAP, 1 bloodstream infection, 
and 2 intra-abdominal infections. Disease severity on admission day measured with SAPS II 
score was similar in colonized and non-colonised patients. SOFA score, a marker of 
response to therapy, improved slower in the colonized patients. Mortality was significantly 
higher in colonized patients, 10 vs 5 deaths, but so was underlying morbidity with 6 vs 1 
patient in the McCabe class C, and 7 vs 18 in the McCabe class A group. Analysing 
mortality irrespective of colonization status, mortality was 57 % in the Mc Cabe class C and 
16 % in the class A group, almost identical to mortality analyzed according to colonization 
status. Colonization with P. aeruginosa was thus associated with higher mortality, but a 
causal effect could not be inferred from this study. 
 
Paper two 
In a cohort of 74 consecutively recruited mechanically ventilated patients, airway samples 
were collected from the oropharynx, the trachea and the distal airways (BAL fluid), 48 
hours after admission to the ICU, and thereafter every 48 hours or until extubated. A second 
sample set was obtained in 47, a third in 28, a fourth in 16, and a fifth in 13 patients, 
respectively. Potential VAP  pathogens were identiﬁed, quantified, and genotyped using 
standard techniques. Microbial ﬁndings were highly correlated both between airway 
locations and over time when samples were taken no more than 72 h apart. If no VAP 
pathogen was present in the oral ﬂora, it was unlikely to find it in the lower airway sample. 
The positive predictive value of the oropharyngeal sample was 0.73 (95% CI 0.67–0.80), 
and the negative predictive value was 0.95 (95% CI 0.92–0.99). Colonisation with 
Enterobacteriacae, nonfermentative bacteria and S. aureus was monoclonal in the airways 
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and over time, whereas colonisation with microbes normally found in the oropharynx, i.e., 
H. inﬂuenzae, and S. pneumoniae, was polyclonal. When antibiotics were used, the chance 
of recovering VAP pathogens from all sampling sites was reduced three-fold. No correlation 
was observed between a bacterial count of ≥104 cfu ⁄ml in BAL ﬂuid and chest X-rays 
compatible with VAP. 
 
Paper three 
Seventy patients were included, 59 with non-cardiovascular diagnosis. Infection was the 
most common diagnosis group (n=25), followed by primarily respiratory problems (n=14), 
gastrointestinal problems (n=8), trauma (n=3) and miscellaneous (n=9).Twenty-five patients 
died.  Median NT-proBNP level in serum 48 h after admission to the ICU was 154 (range 
3–5895) pmol/l,  median NT-proANP level was 1180 (range 283–7020) pmol/l (n =65). NT-
proBNP and NT-proANP levels were significantly higher in non-survivors than in 30-day 
survivors, median (25th–75th percentile): NT-proBNP 438 (282–1356) vs.59 (20–368) 
pmol/l, respectively (P= 0.001), and for NT-proANP 1845 (1190–2780) vs. 993 (692–1890) 
pmol/l (P= 0.002). Patients with supramedian NT-proBNP and NT-proANP levels had a 
higher mortality rate than those with inframedian values, odds ratio (OR) 5.74 (95% CI 
1.91–17.28, P 5 0.002) and 5.74 (95% CI 1.77–18.55, P=0.004). The relative prognostic 
value by the AUC (c-index) was 0,68 for SAPS,  0,74 for log NT-proBNP, 0,73 for log NT-
proANP, increasing to 0, 76 and 0, 75 respectively when combined with SAPS. Thus, NT-
proANP and NT-proBNP levels were both associated with decreased short-term survival in 
unselected, mechanically ventilated ICU patients. NT-proANP performed equally well as a 
prognostic indicator as NT-proBNP and may represent an alternative to NT-proBNP. 
Prospective studies involving a larger number of patients will be needed to determine the 
clinical utility of NT-proANP and NT-proBNP in this setting and to define prognostic cut-
off points. 
 
Paper four 
Seven patients with severe pdm (H1N1) influenza defined by positive airways pdm (H1N1) 
polymerase chain reaction (PCR), bi-lateral diffuse lung chest X-rays infiltrates, need for 
mechanical ventilator support, but without significant co-morbidities, were compared to 7 
age and gender matched healthy controls. Blood samples were collected at inclusion, at day 
3 and 6. Four patients were viremic at inclusion, and in two, in subsequent samples. In two 
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patients with viral loads above 1000 genomes/ml, mutant D222G/N pdmH1N1 virus was 
identified. With micro array analyses, compared to healthy controls and false discovery rate 
(FDR) < 5%), 370 genes were found at least 2-fold up-regulated (N= 259) or at least 50% 
down-regulated (N= 111) in whole blood samples from study inclusion. Among the top up-
regulated genes, several were linked to neutrophil differentiation and activation, or encoding 
neutrophil granule proteins like CD177, MMP-8, S100A12, S100A9 and ANXA3. This up-
regulation continued over time so that on the last sampling day, 14 of the 30 genes with the 
highest fold change, coded for products located in neutrophil secretory granules, linked to 
granulocyte maturation, or having known antibacterial activity. Activation was also seen at 
the protein level, reﬂected by a marked increase in plasma levels of the granulocyte-derived 
enzymes elastase and lactoferrin persisting throughout the observation period. Among 
down-regulated genes, natural killer cell associated genes (e.g., KLRG1, KLRD1 and 
CD244), genes encoding lymphocyte surface markers (CD4, CD2, CD1c, C3XCR1), and 
genes involved in T cell activation like NFATC2 were identiﬁed. Genes encoding antigen 
presenting molecules of MHC II class were consistently down-regulated. Notably, no genes 
encoding inﬂammatory cytokines or interferons were up-regulated. However, several 
cytokine response genes like IFN-a response gene IFI27, and TNF and IL-18 receptor genes 
were up-regulated. Markedly activation of the whole complement cascade was demonstrated 
by high levels of the terminal complement complex (TCC), the elevation being highest in 
the sickest patients. In contrast to the ﬁnding on mRNA level in whole blood, 16 of the 29 
tested cytokines, including interferons, interleukins, chemokines and growth factors, were 
signiﬁcantly elevated in patients at study inclusion versus controls.  
 
Levels of IFN-α, as well as the prototypical pro-inﬂammatory cytokines TNF-α and IL-6, 
Th1 (i.e., IFN-γ), Th17 (i.e., IL-17) and Th2 (i.e., IL-9) derived cytokines, were elevated, as 
well as several chemokines , including both CC chemokines (i.e. MCP-1 and eotaxin) and 
CXC chemokines (i.e. IL-8 and IP-10), with particularly high levels of IP-10 (>100-fold 
increase). In addition to pro-inﬂammatory cytokine increase, the patients showed markedly 
raised levels of the anti-inﬂammatory mediators IL-10 and IL-1Ra (>10-fold). Most of the 
changes in cytokines persisted throughout the observation period. Growth factors involved 
in matrix remodelling, ﬁbrosis and angiogenesis (i.e. FGF, PDGF and VEGF), were also 
elevated with particularly high levels of PDGF (>50-fold). The increased mRNA level of 
MMP-8 in blood was also seen at the protein level in plasma with markedly increased 
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MMP-8 in the patients (>10-fold). This MMP-8 increase was accompanied by a signiﬁcant 
increase in several endogenous tissue inhibitors of MMPs (i.e. TIMP-1, TIMP-3 and TIMP-
3), further underscoring an ongoing process of matrix remodelling in these patients. In 
contrast to MMP-8, no increase in MMP-9, and MMP-12 was found the latter two down-
regulated in the patient group, suggesting that the MMPs were differently affected by severe 
H1N1 inﬂuenza infection. 
4. General discussion 
4.1 Paper one  
P. aeruginosa is among the most frequently isolated pathogens from airway samples of 
patients on invasive mechanical ventilation (151;152). P. aeruginosa is also consistently 
reported in the context of outbreaks (153). Organisms within the Pseudomonas genus are 
highly versatile, adapt to a wide range of habitats, even growing in distilled water, 
accounting for their constant presence in the environment (153). The prevalence of 
colonization in healthy persons outside of hospitals is low (154). In hospitalized patients 
carriage is increased, and is associated to frailty, mechanical ventilation, oral feeding tubes 
and use of antibiotics (155-157). The source and transmission routes of  colonization are 
often difficult to trace, in outbreaks however, contaminated hospital equipment is often 
implicated (153). The first aim of the presented study was to describe an outbreak 
effectively propagated by contaminated oral swabs. This outbreak was part of the largest 
ever P. aeruginosa outbreak in Norway, the contaminated swabs being distributed 
nationwide (158). At our institution colonization occurred early, half of the patients being 
colonized within 4 days after admittance to the ICU; it was widespread with a 41% 
colonization rate, thus reflecting a highly efficacious direct oropharyngeal inoculation route. 
The outbreak was the second with P. aeruginosa in our ICU, the first being caused by 
contaminated tap water and successfully stopped by increasing water temperature in boilers, 
pipes and taps, along with strict barrier nursing methods (159). In the inter outbreak period, 
where a comprehensive P. aeruginosa screening was in place, the recovery rate of P. 
aeruginosa  was less than half the rate during the outbreak, and isolates were  polyclonal, 
testifying to effective cross-contamination precautions, and to the propensity of  P. 
aeruginosa to occur in outbreaks, at least in our ICU. The second aim of the study was to 
investigate the impact of colonization on patient morbidity and mortality. P. aeruginosa 
does not, with few exceptions, such as after inoculation in traumatized skin or ear canal, 
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cause disease in normal hosts (153). P. aeruginosa  possesses several virulence factors 
(160), and trauma to the mucosa,  pooling of contaminated oropharyngeal secretions, and 
creation of a foreign body surface by the endotracheal tube, can all contribute to a transition 
from colonization to infection (66;70). Distinguishing colonization from infection is not 
straightforward in ventilated patients. Therefore, two investigators separately reviewed and 
scrutinised each patient file before categorizing to either of them.When there was 
discrepancy, a consensus was reached after a re-review. Seven of the 18 colonized patients, 
or roughly a third, were considered to be infected. This is lower than in the study presenting 
this outbreak on a national level (158), where 161 out of 231 patients, or roughly two-thirds, 
were considered infected. Though relatively more septicaemias were found, the high 
number of pneumonias explain this difference, confirming the difficulty of separating 
airway colonization from pneumonia, and the subjective nature of this distinction, at least in 
ventilated patients. We found a significantly higher mortality in colonized vs. non-colonized 
patients, 55%, vs. 19%. The two groups were similar for most demographic variables, 
regarding conditions leading to ICU admission, and SAPS II score reflecting disease 
severity at admission. They differed, however, regarding co-morbidity and response to 
therapy. McCabe classification, a marker of co-morbidity was as measure of the former, and 
the rate of decline of the SOFA score for the latter. The death rate in colonized and infected 
patients was similar, but the numbers were too low to warrant formal statistical analysis. 
Colonization was probably not a causal factor for mortality. A similar difficulty, delineating 
cause and association, was also seen in the outbreak investigation on the national level. 
Investigators found underlying disorder to be of major importance, with all 71 deaths 
occurring in patients with severe underlying diseases. They went, however, further in their 
conclusion, stating that in 31 of 71 patients P. aeruginosa infection contributed to death, in 
21 probably not, and in the rest uncertain or not possible to evaluate. Support in the 
literature can be found for either view, colonization with large microbial burdens being an 
independent risk factor for death (161), or colonization per se having no attributable 
mortality, only if leading to VAP (162). A major methodological difficulty in outcome 
studies with this and similar opportunistic pathogens like Stenotrophomonas and 
Acinetobacter, is that risk of acquisition, risk of infection, and risk of death from underlying 
disease covariate, often making it impossible at both single patient level, an in cohorts to 
establish the ultimate cause of death.  
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4.2 Paper two  
In this study of scheduled microbial samplings from three airway locations in long-term 
ventilated patients, several observations were made. By genotyping all isolates considered to 
be potential VAP pathogens, it was demonstrated that they were monoclonal over locations 
and time, implicating that once established colonizing bacteria occupy an ecological niche, 
and there is no constant turnaround of microbes seeding the airways from the environment 
or from other locations in the patient. This applies at least over a period of 72 hours, where 
correlations were found to be between 0, 71 and 0, 88.  Within 17 patients identical bacterial 
clones were found more than 6 days apart, and observation over this time interval was 
possible for 28 patients. The high proportion of patients keeping the same clone over this 
prolonged period, confirms the stability of the established flora. These observations are in 
line with the results from the largest study ever conducted to assess the relevance of 
separating early VAP from late VAP (83). Although  having a different design, comparing 
the distribution of pathogens recovered in patients with early and late onset VAP (early < 7 
days, and late >7 days of invasive mechanical ventilation), in more than 16 000 VAP cases, 
they found no difference pointing to an evolution towards more MDR bacteria over time. 
We found the distribution of potential VAP pathogens nearly identical in samples collected 
2 days and 11-14 days after initiation of ventilation, with exceptions for S. aureus which 
increased in late BAL samples and Candida spp which increased in late oropharyngeal 
samples, but numbers of patients are small. Genotyping showed that bacteria normally 
found in the oropharynx, such as S. penumoniae, H. influenza and H. parainfluenza were 
polyclonal, possibly implicating that monoclonality is observed only with recently 
introduced bacteria, such as Enterobacteriaceae in ventilated patients, but again small 
number of patients preclude too firm conclusions. The observation in this study of an 
equally high correlation of possible VAP pathogens in three sampled locations, oropharynx, 
trachea and BAL fluid, was recently reproduced in a study with a  similar design.(163). 
Here, the authors found that isolates of S. aureus, P. aeruginosa, Acinetobacter species, and 
enteric species recovered from dental plaque from most patients were indistinguishable from 
isolates recovered from BAL fluid, and concluded that “respiratory pathogens isolated from 
the lung are often genetically indistinguishable from strains of the same species isolated 
from the oral cavity in patients who receive mechanical ventilation”. Our suggestion, to use 
results of oropharyngeal surveillance cultures to guide therapy in suspected VAP, was 
recently evaluated in a large study (164). Out of VAP 136 patients with a positive culture 
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collected with a plugged distal bronchial sampling procedure 125 had a positive culture at 
ICU admission. The correlation between these two specimens was 85 %, translating into a 
likelihood ratio > 6, a threshold considered significant to accept the diagnosis. In this study 
VAP diagnosis and sampling was done within 5 days of ICU admission. In another study, 
endotracheal surveillance cultures were collected twice weekly and proved predictive of 
pathogens sampled when VAP was diagnosed, with 83% correlation between the two (165).  
Based on the high correlation between oropharyngeal and endotracheal cultures found in the 
presented study, one might suggest that the even more easily collected oropharyngeal 
samples could be used. Empiric VAP therapy guided by previous surveillance samples is 
still controversial, and Hayon et al did not recommend this strategy due to lack of 
correlation between surveillance and VAP cultures (166). In their study, however, mean 
time from surveillance culture to VAP was 8 days, and cultures collected from locations 
outside the respiratory tract were also considered as surveillance cultures. Thus, surveillance 
has to be performed twice weekly, and only airway samples should be considered relevant 
for surveillance related to VAP diagnostics. Finally, we assessed correlations between 
bacterial counts accepted as thresholds for VAP in distal airway samples and chest X-rays 
suggesting VAP were performed. No such correlation was found, and the lack of correlation 
was not explained by differences in antibiotic usage, as the proportions of patients receiving 
antibiotics and had growth of ≥ 104 CFU ⁄ mL of a VAP pathogen were the same for patients 
with and without inﬁltrates (nine of 18 and 12 of 20, respectively). The strength of this 
analysis was the ability to investigate serial X-rays in a majority of the patients, excluding 
VAP diagnosis where chest X-ray changes were transient. Most VAP studies use single X 
rays to establish the diagnosis of VAP, but it is well recognized that chest X rays infiltrates 
are both common and caused by several conditions other than VAP in ventilated patients, 
and infiltrates caused by pneumonia only resolve over weeks. 
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4.3 Paper three 
 Several prognostic markers have been investigated in different ICU patient populations, 
including patients with VAP and sepsis. Markers of inflammation such as C-reactive protein 
and pro-calcitonin and cytokines (regulating their production) (167-169), as well as markers 
such as cholesterol and thyroid hormones have been evaluated (170;171). The natriuretic 
peptides are a family of structurally related hormones, released from the atria (ANP) or 
ventricles (BNP and ANP) in response to stretch, and thus markers of cardiac wall 
distension (172). In cardiology they have been firmly established as markers of heart failure, 
but also proven their value in other cardiovascular diseases, including congestive heart 
failure, acute coronary syndromes and valvular heart disease (173;174) Both ANP and BNP 
are cleaved upon secretion and their biologically inactive N-terminal end, NT-proBNP and 
NT-proANP are more stable, and preferred for routine measurements. The relative 
prognostic merit of these two markers has been compared in several cardiac conditions such 
as after myocardial infarction, aortic stenosis, and hypertrophic cardiomyopathy (174-176). 
In critically ill patients, their role has been more controversial, and notably in sepsis and 
septic shock association between levels of these peptides and ventricular filling pressure 
have been weak (177). Several mechanisms could contribute to the release of natriuric 
peptides in the critically ill, including right ventricular overload, catecholamine therapy, 
renal failure, diseases of the CNS, and cytokine up-regulation (178). In a recent review, an 
excellent prognostic value of natriuric peptides in ICU patients was reaffirmed (179). There 
are few reports of the relative performance of NT-proBNP and NT-proANP in ventilated 
ICU patients, and they have been reported to be differentially secreted in critically ill 
patients (180). In the presented study we compared their performance as prognostic markers 
in the same population of unselected mechanically ventilated patients. This cohort was the 
same as the one presented in paper two of this thesis, and comprised patients admitted to the 
ICU for mainly non-cardiac conditions, the majority admitted due to infections and lung 
diseases. Blood samples for NT-proBNP and NT-pro ANP measurements were collected 48 
hours after ICU admission, as this sampling time represented the first sampling in the 
airways colonization study, from which these patients were recruited. This delayed sampling 
may explain why the levels were lower than in another study with similar design, where 
sampling was performed at ICU admission (181). In a large Finnish study of patients with 
sepsis and septic shock, NT-proBNP sampled on day three after admission, but not at 
admission, was an independent predictor of mortality, thus optimal sampling time for 
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prognostication need to be defined, and may differ for various patient categories (182). 
Although prognostic value of NT-proBNP has been investigated in several ICU patient 
populations, including unselected ICU patients, less is known about NT-proANP 
(181;183;184). A previous study showed levels to be higher in non-survivors than survivors 
with septic shock (185). The novelty of this study was by means of multivariate regression 
analysis to show that also NT-proANP is an independent prognostic marker, performing 
equally well as compared with NT-proBNP in unselected mechanically ventilated patients. 
The value of NT-proANP as prognostic marker was recently also investigated in lower 
airways infections (186), but the focus of recent research in natriuretic peptides has shifted 
to NT-proBNP.  In the presented study both peptides were significantly higher in non-
survivors than survivors, and in the entire cohort mortality was higher above than 
underneath the median value. In univariate analysis increase of 1 standard deviation 
increased the odds ratio for 30 days mortality with 2,55 (log NT-proBNP) and 2,48 (log NT-
proANP), and the relative prognostic value by the AUC (c-index) was higher than for the 
SAPS II score ( 0,74 and 0,73 vs. 0, 68), and in a combined model with SAPS II marginally 
additive (0,76). A recently published large Finnish multicenter study in unselected 
mechanically ventilated patients including 958 patients also found higher values in 90 days 
non-survivors. The baseline NT-proBNP AUC predicting 90 days mortality was similar to 
ours, 0,718. In this large sample they also determined a baseline cut-off value of 1765 pg/ml 
independently associated with mortality. Still, the authors could not recommend NT-
proBNP for routine prognostic purpose as it did not add any value to other clinical data in 
patients with respiratory failure (187). Thus the role for these markers is still unclear, 
although we would agree with the summary remarks in a recent review of cardiac 
biomarkers in the critically ill: "First, specific assays have limitations, assay cut-offs have 
not been clearly established, and measurements during dynamic critical illness may be 
problematic. Second, biomarker interpretation may vary depending on individual patient 
characteristics and ICU diagnosis. Last, any marker measured in isolation is unlikely to 
surpass careful bedside assessment" (188). 
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4.4 Paper four 
The 2009 pdm(H1N1) pandemic was mild in terms of overall mortality, with death rates not 
significantly higher than during seasonal epidemics (189). There was, however, a marked 
difference in age-specific mortality rates, with a higher mortality rate in the young without 
serious underlying co-morbidity, and a lower mortality than for seasonal influenza epidemic 
in the elderly, a situation reminiscent of the 1918 pandemic (189). A foreboding of such a 
scenario came from reports in the southern hemisphere predating the pandemic on the 
northern by a few months (190), enabling us to design a prospective study targeting patients 
with serious respiratory failure, investigating putative viral factors and host responses 
explaining the serious outcome of pdm(H1N1) infection. The pathogenesis of the lower 
respiratory tract pdm(H1N1) is poorly understood. The reconstructed 1918 H1N1 virus and 
the highly pathogenic H5N1 virus have a different genetic basis for their virulence, but 
share a phenotype of highly effective replicative capacity, and the induction of a strong 
cytokine production ("cytokine storm") (191). Viral load at the site of infection is thus 
important for  subsequent inflammatory and tissue damaging response. This was recently 
demonstrated for pdm(H1N1) infection in a macaque model, were immunohistochemistry 
showed that, compared to seasonal influenza, pdm(H1N1) virus caused significantly more 
pulmonary lesions, correlated to more abundant virus in the lower respiratory tract. (192). 
Interestingly, the inflammatory response was not qualitatively but quantitatively different, 
gene expression profiles from lung tissue in seasonal and pdm(H1N1) being similar. A 
correlation between pharyngeal viral load and cytokine production was also recently 
published in a clinical study of severe pdm(H1N1) infection (193).  In the presented study, 4 
out of 7 patients had viremia, which is otherwise rare in seasonal influenza. It is conceivable 
that the observed viremia reflect both a large viral load in the lungs, indicative of effective 
replicative capacity, and a disruption of the alveolar capillary integrity caused by ensuing 
inflammation. Secondly, two out of four viremic patients displayed the D222G/N mutation 
as the viremic strain, as opposed to 222D in their airway samples. One of the remaining two 
had a 222D in both airway and serum, while viral load was too low to allow sequencing for 
the last viremic patient. The finding of D222G/N mutant lends further credit to viral factors 
as important in determining outcome in severe pdm(H1N1) influenza. In a recent study, 
viremia was found to be strongly associated with severe outcome in pdm(H1N1) and was 
detected in 14 out of 139 hospitalized patients, the D222G/N quasispecies detected in 90% 
of the viremic patients and thus strongly correlated to viremia (193). The capacity for 
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increased binding of the D222G/N mutant to cells of the lower respiratory tract, was 
recently demonstrated in a study were the D222G/N mutation was introduced  in a prototype 
pdmH1N1 by reverse genetics, and the effect on virus receptor binding, replication, 
antigenic properties, and pathogenesis and transmission in animal models was investigated 
(194). Here, increased binding to macrophages and type II pneumocytes in the alveoli, and 
to tracheal and bronchial submucosal glands was demonstrated. This observation could 
explain why we did not find peripheral blood gene expression of up-regulated pro-
inflammatory cytokines, but elevated cytokine levels in peripheral blood, the site of 
production possibly being infected pulmonary macrophages and type II pneumocytes. These 
findings were recently replicated in a study showing up-regulation of pro-inflammatory 
cytokines in lung tissue, but down-regulated in peripheral blood leukocytes, in patients 
dying of pdm(H1N1) influenza (195). Further support for pulmonary and not peripheral 
blood production of pro-inflammatory cytokines are reports of higher TNF and IL-1 
concentrations in BAL fluid than in serum in patients with ARDS, suggesting pulmonary 
production (102;196). The histopathological findings in severe pdm(H1N1) infections are 
diffuse alveolar damage (DAD) with alveolar hyaline membranes, the histopathological 
correlate of ARDS (197;198). In viral pneumonia, the histopathological changes are 
interstitial lymphocytic infiltrate without alveolar exudates. The line between severe viral 
pneumonia and ARDS is blurred and more semantic than biologic, the former being 
etiologically defined and the latter as a clinical syndrome. Infections are, however, 
recognized as a major cause of ARDS, and in the context of severe pdm(H1N1) infection, 
where  a longer and more severe immune response culminate in a more destructive viral 
infection, the term is appropriate. Patients in this study were too unstable to tolerate 
sampling from the lungs, the primary site of inflammation. We thus had to resort to blood 
sampling for investigation of the host immune response. Blood represents both a reservoir 
and a migration compartment for cells exposed to infectious agents and taking part in 
inflammatory processes, and constitutes an accessible source of information representing 
host immune response (43).  Micro-array analyses identified 370 genes at least 2 fold up or 
50% down-regulated compared to healthy controls, with a FDR < 5%. The analyses were 
repeated and results confirmed by real time quantitative PCR (RT-qPCR) for selected genes. 
A criticism of this study is the lack of control group with less severe disease, making a 
quantitative analysis of the immune response in severe and less severe disease difficult. The 
micro-array analysis using a healthy control group had the advantage of making a 
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qualitative analysis of involved immune response genes easier. Gene-expression profile in 
healthy controls were markedly similar, thus a clear distinction could be made towards sick 
patients, with multiple testing of 22 000 genes and FDR < 5% still identifying 370 
differentially expressed genes. In a second set of analysis examining gene expression  in 
patients on the first and last day of sampling, expression diversity was too great to allow 
application of the FDR <5% criteria, as no differentially expressed genes would have been 
discovered. Though eliminating false positive gene-expression differences, an unacceptably 
high rate of false negative would have been created. A similar situation regarding micro-
array analysis could be envisaged comparing severe and less severe pdm(H1N1) patients, 
given the limited number of patients that could be recruited during the short pandemic peak. 
Considering the dynamic nature of the immune response, temporal differences in sampling 
are of major importance. This study was not primarily a micro-array study, and the full 
spectrum of possible micro-array analysis was not performed. The Ingenuity® analysis tool 
was used for analysing gene networks and pathways, identifying inflammatory response, 
infectious disease and pulmonary disease as the categories with the most up-regulated 
genes. Based on findings in several earlier publications, a hypothesis-driven analysis was 
also performed, suggesting a prominent role of neutrophiles in the pathogenesis of ARDS 
(199;200). The observation of several genes involved in neutrophile differentiation, 
activation, or encoding neutrophile granules, this gene-expression profile increasing over 
the observation period leading to 14 of the 30 most up-regulated genes belonging to this 
category on the last sampling day, strengthen the hypothesis. A pattern of down regulation 
of T-cell surface markers, like CD4, CD2, CD1c and T-cell activation markers such as 
NFATC2 was also observed, as well as consistent down-regulation of MHC II class 
molecules, possibly pointing to defective antigen presentation and impairment of 
development of adaptive immunity in severe pdm(H1N1). This was also shown in a recent 
study with similar design, but with far more comprehensive and formal analysis of the 
micro-array data, suggesting impairment of adaptive immunity development allowing 
persistent viral replication and continued cytokine production (201) . Our findings of 
persistent viremia in two out of four patients and the persistent elevation of cytokines over 
the study period could strengthen this interpretation. The micro-array results were further 
confirmed on the protein level, demonstrating persistent high levels of the neutrophile 
mediators MMP8, elastase, and lactoferrin, the former two involved in tissue degradation 
and remodelling.  The role of these proteases in the pathogenesis of neutrophile-mediated 
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lung injury and ARDS is increasingly recognized (202-204). In particular, the elastinolytic 
activity of elastase is recognized to be central to alveolar injury seen in acute and chronic 
lung disease (205;206). In influenza infections the complement system is activated via the 
classical pathway by binding to virus specific neutralizing antibodies. However, alternative 
activation pathways have been demonstrated, and complement activation via non-
neutralizing natural antibodies (representing the spontaneous repertoire of circulating 
immunoglobulin's, i.e. not generated after pathogen exposure), has been shown to mediate 
influenza neutralization in a similar way (207). In the present study high levels of the 
terminal complement complex (TCC) demonstrate both a strong activation, and activation 
involving the whole complement cascade. Viremia could have contributed to the activation, 
and the host-damage capacity of unchecked complement activation could have contributed 
to the seriousness of the disease. The most pronounced activation was found in the two 
patients with mutant virus and the most serious clinical outcome, lending further credit to 
this notion. Complement activation is an upstream mediator in the immune system, leading 
to activation of granulocytes, monocytes and macrophages. An alternative or additional role 
of the complement activation seen in this study could have been enhancement of excessive 
cellular innate immune response. A broad panel of cytokines, chemokines and growth 
factors was also investigated.  Sixteen out of 29 tested cytokines including intereferons, 
interleukins, chemokines and growth factors were significantly up-regulated, and in this 
longitudinal study, elevations were consistent over the observation period of 6 days. The 
prototypical pro-inflammatory cytokines TNF-α and IL-6 were markedly up-regulated as 
well as the Th1 derived IFN-α, and Th17 derived IL-17 cytokines, and the anti-
inflammatory mediators  Il-10 and Il-1Ra reflecting a net inflammatory phenotype in severe 
pdm(H1N1). Il-8 is the major neutrophile chemoattractant to the lungs, and can be secreted 
in large quantities by lung fibroblasts and type II epithelial cells (208). Il-8 in BAL fluid has 
also been shown to be a potential marker of development of ARDS,  and serum levels of 
both IL-8 and IL-6 have been shown to correlate with the severity of ARDS, and lately 
specifically with pdm(H1N1) (206;209;210). Particularly high levels of IP-10 (> 100 fold), 
a CXC chemokine causing migration and activation of T-cells and NK cells into inflamed 
tissue were seen. The highest levels were observed in the two sickest patients as for TCC, 
possibly pointing to excessive production contributing to non-resolving systemic and 
pulmonary inflammation. Markedly enhanced level of growth factors involved in matrix 
remodelling, fibrosis and angiogenesis (FGF, PDGF >50 fold, VEGF) together with the 
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elevated elastase and MMP8 levels could indicate an ongoing pulmonary remodelling 
characteristic of severe respiratory disease. Conflicting results regarding the 
cytokine/chemokine profile in severe pdm(H1N1) have been reported. Bermejo-Martin et al 
found a similar Th1 and Th 17 cytokine/chemokine up-regulation in severe infections with 
high TNF-α ,INF-γ / IP-10, MCP-1, and IL-17, IL-8 and IL-6 levels, respectively (210). A 
strong Th 1,Th 17 response was also found by de Castro et al (211). A similar pattern was 
recently published in a study from Hong-Kong (212). High levels of IL-6 and TNF- α was 
confirmed while IP-10 level in contrast, down-regulated in another recent paper (213). The 
reason for this discrepancy for IP-10 is unclear. 
In summary, severe outcome in pdm(H1N1) is correlated to viremia and the D222G/N 
mutant. The lung histopathology and clinical picture in severe disease is similar to ARDS of 
other causes, the immunological mechanisms responsible for tissue damage overlap, an 
impairment of adaptive immunity could explain continuous viremia and persisting immune 
stimulation, and the cytokine profile over several studies is broadly similar, displaying a 
Th1, Th17 response and  high levels of IP-10. 
5. Concluding remarks 
 
In studying the airway microbiology of mechanically ventilated patients, we have shown 
that these patients are vulnerable to colonization with opportunistic bacteria from the 
environment, and contaminated medical equipment poses a particular threat. Colonization 
with P. aeruginosa, one of the most frequently isolated pathogens in the airways of 
ventilated patients, is associated with mortality, but in this study it remains unclear if the 
relation is causal, as underlying co-morbidity was more severe in colonized patients. The 
microbial flora which is established in the airways of ventilated patients is stable over time, 
and potential VAP pathogens recovered from the distal airways, are almost always present 
also in the oropharynx. A possible consequence of this finding is to perform surveillance 
sampling of the easily accessible oropharynx to guide antibiotic treatment of VAP. 
Correlation between findings of bacteria above the quantitative threshold considered 
diagnostic for VAP and chest X-ray compatible with pneumonia was poor, and this study 
challenges the utility of this criterion. NT-proBNP and NT-proANP were equal and strong 
prognostic markers in unselected mechanically ventilated patients, but whether they add 
clinical relevant information in prognostication need further investigation, and cut off levels 
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have to be defined in larger studies. A mutant pdm(H1N1) influenza virus, the D222G/N 
mutant, conferring higher virus binding to the lungs could be one reason for severe outcome 
of influenza infection. The immune response in severe influenza with respiratory failure is 
characterized by Th1, Th17 cytokine response and high levels of IP-10, a marked 
neutrophile and complement activation, and down regulation of T-cell markers, possibly 
pointing to impairment of adaptive immunity.  
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